View Post

T-DM1 for Advanced HER2-positive Breast Cancer: The Royal Marsden Experience

In Clinical Studies News by Barbara Jacoby

By: Dawn O’Shea From: Real-world data from the Royal Marsden Hospital show that the side effect profile of ado-trastuzumab emtansine (T-DM1) in the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer is similar to that shown in clinical trials. However, there are a number of differences. A study published in  Cancer Treatment and Research Communications …